 |
 |
| Home |
| Clinical Trial Search |
| Mailing List |
| Clinical Trial FAQs |
| Participation FAQs |
| Clinical Trials Glossary |
| About Informed Consent |
| Medical Research Areas |
| Clinical Trial Links |
| How to use this System |
|
This site is intended for U.S. residents only. For Novartis Worldwide, Click here |
|
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
|
|
|
|
|||
Clinical Trial Search
Prostate Cancer
Prostate cancer is a tumor that grows in the prostate gland in men. The most common type of prostate cancer is that which originates within the tiny glands of the prostate. This glandular cancer is called adenocarcinoma. Prostate cancer is the most common cancer, excluding skin cancers, in American men.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Prostate Cancer Study CEPO906A2229
Novartis Oncology is conducting a clinical research study to evaluate the difference in effectiveness and safety between the investigational drug patupilone and the drug docetaxel, in people who have hormone refractory prostate cancer. The reason for this study is to find out which of these two medicines gives better relief of prostate cancer. Participants who agree to join in this study, may get either 10 mg/m2 patupilone once every three weeks or 75 mg/m2 of docetaxel once every three weeks, intravenously (directly into a vein). Prednisone will be given to all participants as supportive therapy. Patupilone is a medicine which has not been approved by the FDA (US Food and Drug Administration) for the treatment of people with prostate cancer. Docetaxel is a medication approved by the FDA to treat breast cancer, non-small cell lung cancer and prostate cancer. This study is open-label, which means that after participants are randomly assigned to a treatment, they will know which medication they are receiving.
Trial phase: Phase 2 Participation Duration: Participants will be required to visit the study site approximately once every three weeks for treatment and evaluations for a total of 20 weeks. Protocol Number: CEPO906A2229 Prostate Cancer Study CLBH589C2208
The purpose of this clinical trial is to find out the effects, both good and bad, of a study drug called panobinostat (LBH589) when given to people that have hormone refractory prostate cancer (HRPC) that is no longer responding to treatments that have already been given. The study drug Panobinostat (LBH589) is a medicine which has not been approved by FDA or other Health Authorities for the treatment of any medical conditions. Panobinostat (LBH589) is being tested in this study but is currently not “on the market” (available for you to buy) in any country.
Trial phase: Phase 2 Participation Duration: Participants will be asked to visit the doctor’s office or clinic from 1 to 2 times every week for the first three weeks for treatment and evaluations. They will be asked to visit the doctor’s office once a week on treatment days starting in the fourth week of the study unless they experience any side effects from the study medications. Each visit should take about 1-3 hours; however, on day 1 of the first cycle, participants will be in the office for 9 to 10 hours. Protocol Number: CLBH589C2208 |
